Insight-004 clinical trial update
Immutep updates progress on the INSIGHT-004 Phase I trial testing eftilagimod alpha with avelumab in advanced solid tumor patients.
immutep.comCrawled Nov 15, 2026
Immutep updates progress on the INSIGHT-004 Phase I trial testing eftilagimod alpha with avelumab in advanced solid tumor patients.
Immutep develops immunotherapies targeting Lymphocyte Activation Gene-3 (LAG-3) for cancer and autoimmune diseases.
OncoImmune’s eftilagimod alpha combined with Merck’s pembrolizumab achieves a **17.6-month median overall survival** in first-line treatment of **PD-L1-negative head and neck squamous cell carcinoma (HNSCC)** patients. The trial results highlight a potential therapeutic option for a subgroup of patients historically unresponsive to checkpoint inhibitors. Researchers emphasize the need for further validation in larger studies.
Immutep’s LAG-3 inhibitor **eftilagimod alpha** shows promising overall survival results when combined with **Merck’s Keytruda** in first-line **head and neck cancer** trials. Analysts describe the data as 'impressive,' suggesting potential for accelerated approval. The therapy targets immune checkpoint pathways to enhance anti-tumor responses.
Avelas Biosciences’ eftilagimod alpha combined with pembrolizumab and chemotherapy shows improved survival trends in patients with advanced nonsquamous non-small cell lung cancer (NSCLC). Early-phase trial data highlight the potential of the triple therapy to enhance treatment outcomes for this patient group.
Immutep Limited reports encouraging findings in its head and neck cancer treatment research. CEO Marc Voigt highlights the company’s latest clinical progress, though specific details remain undisclosed. The results suggest potential advancements in immunotherapy for oncology.
A clinical trial demonstrates that the immunotherapy combination of **eftilagimod alpha** and **pembrolizumab** achieves responses in patients with **head and neck squamous cell carcinoma**, including those with low **PD-L1 expression**. Early results suggest potential efficacy where prior single-agent immunotherapy has shown limited success.
A clinical trial evaluates **eftilagimod alpha** combined with radiotherapy and **pembrolizumab** for treating soft tissue sarcoma. Early results show the triplet therapy is well tolerated by patients and demonstrates signs of clinical response. The study highlights potential for this combination in addressing refractory sarcoma cases.

Immutep is a late clinical-stage biotechnology company developing LAG-3 immunotherapies for cancer and autoimmune patients.